Enhancing T-cell response with monoclonal antibodies and chemotherapy in advanced gastric cancer

Table 1 Main results on response rate

Marker/biomarker	Baseline values	After treatment	Clinical response rate (CR + PR)	P value
CEA
	15.2 (1.5-180.5)	6.1 (0.5-55.0)		< 0.001
		≥ 50% reduction	70.0% (CR + PR)	< 0.05
		< 50% reduction	40.0% (CR + PR)	< 0.05
CA19-9
	60.5 (10.5-1000.0)	26.4 (5.0-400.0)		< 0.001
		≥ 50% reduction	75.0% (CR + PR)	< 0.05
		< 50% reduction	42.9% (CR + PR)	< 0.05
CA72-4 (U/mL)
	8.0 (1.5-300.0)	2.8 (0.5-80.0)		< 0.001
		≥ 50% reduction	72.2% (CR + PR)	< 0.05
		< 50% reduction	38.5% (CR + PR)
CD3+ (%)
	62.5 (45.0-75.0)	70.0 (50.0-85.0)		< 0.05
CD4+ (%)
	30.0 (20.0-45.0)	40.0 (25.0-55.0)		< 0.05
CD8+ (%)
	28.5 (15.0-40.0)	22.0 (10.0-35.0)		< 0.05
CD4+/CD8+ ratio
	1.2 (0.6-2.5)	1.8 (0.8-3.5)		< 0.05
CD4 + /CD8 + ratio
		≥ 1.5-fold increase	71.4% (CR + PR)	< 0.05
		< 1.5-fold increase	41.7% (CR + PR)

CR: Complete response; PR: Partial response.